SCHEMBL17316355

SCHEMBL17316355

CC1(COc2ccc(CC(=O)O)cc2)COC1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.54
CACNA1H O95180 6/20 0.49
CACNA1G O43497 1/20 0.49
CACNA1I Q9P0X4 1/20 0.49
FFAR1 O14842 5/20 0.46
PLA2G4B P0C869 1/20 0.44
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
PTGS1 P23219 1/20 0.41
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
RXRG P48443 1/20 0.41
SLC5A1 P13866 1/20 0.41
SLC5A2 P31639 1/20 0.41
PPARD Q03181 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17316426 0.82 ACACB (0.52) ACACBCACNA1HCACNA1GCACNA1IFFAR1
SCHEMBL17316761 0.82 CACNA1H (0.49) ACACBCACNA1HCACNA1GCACNA1IFFAR1
SCHEMBL9935890 0.82 ACACB (0.50) ACACBCACNA1HCACNA1GCACNA1IFFAR1
SCHEMBL5095969 0.82 ACACB (0.50) ACACBPLA2G4BPOLBRXRARXRB
SCHEMBL26454383 0.81 ACACB (0.52) ACACBCACNA1HCACNA1GCACNA1IFFAR1
SCHEMBL17316545 0.81 CACNA1H (0.50) ACACBCACNA1HPLA2G4BKDM4EPOLB
SCHEMBL6304640 0.78 PARP10 (0.54) ACACB
SCHEMBL3048952 0.77 ACACB (0.44) ACACBFFAR1SLC5A1SLC5A2
SCHEMBL17316710 0.76 KCNH2 (0.49) CACNA1HCACNA1GCACNA1IPTGS1RXRA
SCHEMBL13724692 0.76 ACACB (0.46) ACACBCACNA1HCACNA1GCACNA1IFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106414429-B Pyrazole compounds and their use as T-type calcium channel blockers 爱杜西亚药品有限公司 2020-01-03 CN disclosed
US-10065929-B2 Pyrazole compounds and their use as T-type calcium channel blockers IDORSIA PHARMACEUTICALS LTD (CH) 2018-09-04 US disclosed
EP-3194374-B1 TRIAZOLE COMPOUNDS AS T-TYPE CALCIUM CHANNEL BLOCKERS IDORSIA PHARMACEUTICALS LTD (CH) 2018-08-01 EP disclosed
US-20180105496-A1 PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS IDORSIA PHARMACEUTICALS LTD (CH) 2018-04-19 US disclosed
US-9932314-B2 Pyrazole compounds and their use as T-type calcium channel blockers IDORSIA PHARMACEUTICALS LTD (CH) 2018-04-03 US disclosed
EP-3152199-A1 PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS Actelion Pharmaceuticals Ltd. (CH) 2017-04-12 EP disclosed
US-20170096399-A1 PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS IDORSIA PHARMACEUTICALS LTD (CH) 2017-04-06 US disclosed
WO-2015186056-A1 PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS ACTELION PHARMACEUTICALS LTD (CH) 2015-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10065929-B2 Pyrazole compounds and their use as T-type calcium channel blockers CACNA1E, CACNA1I, CACNA1G ACACB 4258/4885CACNA1H 4/4885CACNA1G 3/4885
US-20170096399-A1 PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS CACNA1E, CACNA1I, CACNA1G ACACB 4258/4885CACNA1H 4/4885CACNA1G 3/4885
US-20180105496-A1 PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS CACNA1E, CACNA1I, CACNA1G ACACB 4258/4885CACNA1H 4/4885CACNA1G 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.